Pillar Biosciences Launches Innovative NGS Panel for Tumor Profiling

Introduction

In an exciting development in the realm of cancer diagnostics, Pillar Biosciences, Inc., a pioneer in Decision Medicine™, has announced the launch of their latest innovation: the oncoReveal® Lymphoid next-generation sequencing (NGS) panel. This research-use-only (RUO) kit is set to revolutionize the way laboratories conduct tumor profiling for lymphoid malignancies, allowing them to perform analyses rapidly and effectively.

What is oncoReveal® Lymphoid?

The oncoReveal Lymphoid panel is specifically designed to evaluate a comprehensive set of 84 genes, among which includes the full coding DNA sequence (CDS) of 29 crucial genes. This single-tube NGS workflow is fully automatable and requires only standard equipment found in NGS-equipped laboratories, enabling clinicians to adopt advanced testing methodologies without extensive additional investment.

According to ShiPing Zou, Sr. Director of Product Management at Pillar Biosciences, this product aims to meet the needs of local laboratories seeking efficient and rapid testing solutions for lymphomas. He emphasized, "oncoReveal Lymphoid is compatible with our existing heme-oncology offerings including oncoReveal Myeloid and oncoReveal Heme Fusion. Together, these products cover the complete scope of tumor profiling requirements for molecular pathology labs."

Advanced Technology Behind the Panel

Pillar's oncoReveal Lymphoid leverages unique proprietary technology known as Stem-Loop Inhibition-Mediated amplification (SLIMamp®). This innovative approach employs a tiled amplicon-based library preparation process that ensures the accuracy of genetic profiling down to a precise variant allele frequency (VAF) of 2%. Furthermore, the panel is integrated with PiVAT®, an automated secondary bioinformatics software designed to enhance the sensitivity and specificity of somatic mutation detection from DNA samples.

The compatibility of Pillar's PiVAT technology with other clinical reporting solutions underscores its flexibility and appeal to various healthcare providers, ultimately facilitating enhanced patient care through precise genetic insights.

The Urgency for Rapid Tumor Profiling

With alarming statistics highlighting the frequent occurrence of blood cancers, approximately every three minutes another individual in the U.S. receives a diagnosis of leukemia, lymphoma, or myeloma. For 2024, experts estimate that a staggering 187,740 individuals will be newly diagnosed with these conditions, representing about 9.4% of the nearly 2 million new cancer diagnoses anticipated in that year. Globally, the incidence of lymphoid malignancies exceeded 1.6 million cases in 2021.

These statistics not only underline the urgency for effective diagnostic tools but also emphasize the role of advanced technologies such as oncoReveal Lymphoid in improving patient outcomes. By enabling quicker identification and profiling of tumors, this innovative technology could potentially lead to timely interventions and better management strategies for patients.

About Pillar Biosciences

Pillar Biosciences stands at the forefront of Decision Medicine™, utilizing highly precise and sensitive NGS technologies to inform oncology practice. Their innovations are designed to streamline the testing process, reduce diagnostic costs, and enhance the accessibility and efficiency of sophisticated NGS testing worldwide. Currently, the company offers over 20 NGS testing kits in both IVD and RUO formats, further solidifying its position as a leader in the field. Their facilities located in Natick, Massachusetts, serve as a hub for ongoing advancements in cancer diagnostics.

For more information and updates on their latest offerings, visit pillarbiosci.com and connect with them on LinkedIn.

Conclusion

With the launch of oncoReveal Lymphoid, Pillar Biosciences is setting a new standard in tumor profiling for lymphoid malignancies. This initiative not only exemplifies the company's commitment to advancing precision medicine but also the dedication to improving the efficiency and effectiveness of cancer diagnostics across the board.